Dong-A ST Neurobo Presents Weight Loss Effects of Obesity Treatment at American Diabetes Association Meeting

Confirmed Effectiveness of Obesity Treatment Drug 'DA-1726'

Dong-A ST and its U.S. new drug development subsidiary Neurobo Pharmaceuticals announced on the 28th that they presented the weight loss efficacy results of the obesity treatment drug 'DA-1726' at the 83rd American Diabetes Association (ADA) held at the San Diego Convention Center in the United States from the 23rd to the 26th.

Cha Yuna, Team Leader of the Research Headquarters at Dong-A ST, is presenting the non-clinical efficacy results of DA-1726 at the 83rd American Diabetes Association (ADA) conference held in San Diego, USA, on the 25th (local time).
[Photo by Dong-A ST]

The American Diabetes Association is a prestigious international conference related to diabetes. Dong-A ST and Neurobo Pharmaceuticals presented preclinical research data on DA-1726 through poster and oral presentations.

DA-1726 is a new drug candidate under development as an obesity treatment in the oxyntomodulin analogue class. It acts simultaneously on glucagon-like peptide (GLP)-1 receptors and glucagon receptors to suppress appetite, promote insulin secretion, and increase basal metabolic rate in peripheral tissues. Ultimately, this induces weight loss and blood glucose control.

According to preclinical research data, DA-1726 showed superior weight loss effects in obese animal models despite similar food intake to the GLP-1 analogue semaglutide. Compared to the GLP-1 and GIP dual agonist tirzepatide, DA-1726 demonstrated similar weight loss effects even with higher food intake. It also showed superior improvements in metabolic indicators such as glucose, triglycerides, and total cholesterol compared to tirzepatide.

Furthermore, through glucagon-like action that increases energy metabolism, DA-1726 was confirmed to promote energy consumption by increasing the expression of Ucp1 and Ppargc1a, which are involved in increasing basal metabolic rate in white adipose tissue, thereby inducing excellent weight loss effects.

In a comparative preclinical study with cotadutide, another oxyntomodulin analogue, DA-1726 showed superior weight loss effects compared to cotadutide and demonstrated reductions in plasma triglycerides and total cholesterol (T-CHO). Improvements in insulin and insulin resistance were confirmed in the homeostasis model assessment (HOMA-IR), suggesting the potential for future indication expansion to diabetes, according to Dong-A ST.

A Neurobo Pharmaceuticals official stated, "According to the preclinical results of DA-1726, effective weight loss and blood glucose control are expected," and added, "Based on the excellence of DA-1726, we will do our best to submit the global Phase 1 clinical trial application (IND) smoothly in the second half of this year."

This content was produced with the assistance of AI translation services.